Axsome Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
Total 1Q 2026 net product revenue of $191.2 million, representing 57% year-over-year growth AUVELITY® 1Q 2026 net product sales of $153.2 million, representing 59% year-over-year growth SUNOSI® 1Q 2026 net product revenue of $33.9 million, representing 34% year-over-year growth SYMBRAVO® 1Q 2026 net product sales of $4.1 million AUVELITY approved for the treatment of agitation […]
Original Source
Read the full article at Financialpost →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.